DiaMedica Therapeutics Inc.

NASDAQ:DMAC

Biotechnology

Healthcare
$8.38 -0.17%

-$0.01 today

Market cap
$452.16M
Beta
1.00
P/E (TTM)
-8.8
EPS (TTM)
-$0.65
52W Low $3.48High $10.42

Volume 0.29M

Average 0.19M

Returns on capital

DiaMedica Therapeutics Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-58.4%

avg -95.0%

ROIC

-61.0%

avg -92.4%

ROA

-53.4%

avg -128.0%

Analysis

ROA is currently the strongest return metric at -53.4% versus its period average of -128.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Dietrich John Pauls

President, Chief Executive Officer & DirectorUSD 1.07M55128.79K0.24%

Julie Krop

Chief Medical OfficerUSD 675.67K600<0.01%

Scott Kellen

Chief Financial Officer & Corporate SecretaryUSD 609.87K61225.00K0.42%

Ambarish Shah

Chief Technology Officer————

Dominic R. Cundari

Chief Commercial Officer—7515.00K0.03%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 10, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

6

$6.41M

Sells

0

$0.00

Net Transaction Value

+$6.41M

Net buying

Most Active

STAHLBERG JAN

6 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 25, 25

STAHLBERG JAN

Indirect

Buy$626.8K
Nov 24, 25

STAHLBERG JAN

Indirect

Buy$317.7K
Nov 21, 25

STAHLBERG JAN

Indirect

Buy$1.5M
Nov 20, 25

STAHLBERG JAN

Indirect

Buy$951.2K
Nov 19, 25

STAHLBERG JAN

Indirect

Buy$1.7M
Nov 18, 25

STAHLBERG JAN

Indirect

Buy$1.2M

Summary

Insiders reported 6 buys worth $6.41M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $6.41M. STAHLBERG JAN was the most active insider with 6 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does DiaMedica Therapeutics Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about DMAC's management, answered from reported figures.

Who manages DMAC?

DiaMedica Therapeutics Inc. (DMAC) lists 5 active executives. The top listed executive is Ambarish Shah, Chief Technology Officer.

Are DMAC insiders buying or selling?

Recent insider activity shows net buying of $65.29M.